SCHEMBL15922649

SCHEMBL15922649

C=COCC(CCCCCCC)CCCCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
TSHR P16473 4/20 0.40
FDPS P14324 3/20 0.36
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
DNM1 Q05193 2/20 0.34
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
SMPD1 P17405 2/20 0.33
OPRM1 P35372 1/20 0.33
THRB P10828 1/20 0.33
CYP3A4 P08684 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15922971 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL15922096 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL2870768 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL15922428 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL15922987 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL18675773 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL2870770 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL15923040 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL17311977 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2
SCHEMBL15923191 1.00 LMNA (0.45) LMNATSHRFDPSPRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180210362-A1 METHOD OF PRODUCING CURABLE LIQUID DEVELOPER AND CURABLE LIQUID DEVELOPER CANON KK (JP) 2018-07-26 US disclosed
US-20180143546-A1 METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2018-05-24 US disclosed
US-9971268-B2 Curable liquid developer having a cationically polymerizable liquid monomer with a monofunctional vinyl ether compound CANON KABUSHIKI KAISHA (JP) 2018-05-15 US disclosed
US-9926474-B2 Pressure-sensitive adhesive compositions and adhesive articles including the same 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-03-27 US disclosed
US-20180059566-A1 UV-CURABLE LIQUID DEVELOPER, FIXING METHOD, IMAGE FORMING METHOD, AND UV-CURABLE COMPOSITION CANON KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-9897936-B2 Method of producing curable liquid developer and curable liquid developer CANON KABUSHIKI KAISHA (JP) 2018-02-20 US disclosed
US-20180046105-A1 CURABLE LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2018-02-15 US disclosed
US-20180046106-A1 LIQUID DEVELOPER AND METHOD OF PRODUCING SAID LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2018-02-15 US disclosed
US-9891546-B2 Ultraviolet-curable liquid developer CANON KABUSHIKI KAISHA (JP) 2018-02-13 US disclosed
US-9891547-B2 Ultraviolet-curable liquid developer CANON KABUSHIKI KAISHA (JP) 2018-02-13 US disclosed
US-20160349652-A1 METHOD OF PRODUCING CURABLE LIQUID DEVELOPER AND CURABLE LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2016-12-01 US disclosed
EP-3098659-A1 CURABLE LIQUID DEVELOPER AND IMAGE-FORMING METHOD USING CURABLE LIQUID DEVELOPER Canon Kabushiki Kaisha (JP) 2016-11-30 EP disclosed
WO-2016171284-A1 CURABLE LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2016-10-27 WO disclosed
WO-2016111380-A1 ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF CANON KABUSHIKI KAISHA (JP) 2016-07-14 WO disclosed
US-20150353785-A1 PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS AND ADHESIVE ARTICLES INCLUDING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2015-12-10 US disclosed
EP-2951257-A1 PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS AND ADHESIVE ARTICLES INCLUDING THE SAME 3M Innovative Properties Company (US) 2015-12-09 EP disclosed
CN-104981528-A Pressure-sensitive adhesive compositions and adhesive articles including the same 3M INNOVATIVE PROPERTIES CO 2015-10-14 CN disclosed
US-20150192875-A1 ULTRAVIOLET-CURABLE LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2015-07-09 US disclosed
US-20150192875-A1 ULTRAVIOLET-CURABLE LIQUID DEVELOPER CANON KABUSHIKI KAISHA (JP) 2015-07-09 US disclosed
WO-2014120593-A1 PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS AND ADHESIVE ARTICLES INCLUDING THE SAME 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180046106-A1 LIQUID DEVELOPER AND METHOD OF PRODUCING SAID LIQUID DEVELOPER CCNA1, CCNT1, AUP1 LMNA 417/4885TSHR 1057/4885FDPS 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.